Comparison

Sermorelin vs Tesamorelin: Evidence-Based Comparison

Compare Sermorelin and Tesamorelin: dosing, mechanisms, safety profiles, and research evidence. Citation-backed comparison.

Overview

A comparison of Sermorelin and Tesamorelin as GHRH analogs, including half-life differences, FDA approval status, clinical evidence, and research protocol context.

Compared compounds

Sermorelin Tesamorelin

Overview

Sermorelin and Tesamorelin are both GHRH analogs studied for growth hormone stimulation, but they differ in structure, half-life, regulatory history, and the depth of their published evidence bases. Tesamorelin has an FDA-approved indication for HIV-associated lipodystrophy, giving it a more formal clinical evidence foundation than Sermorelin.

Mechanism Comparison

Both compounds are synthetic GHRH analogs acting on the pituitary to stimulate endogenous GH release. Sermorelin is a truncated 29-amino acid analog of natural GHRH, while Tesamorelin is a full-length GHRH analog modified with a trans-3-hexenoic acid group that extends its half-life and bioavailability. The structural difference results in meaningfully different pharmacokinetics.

Dosing and Protocol Comparison

Sermorelin is typically studied at daily subcutaneous doses in the 200–500 mcg range with a short half-life requiring once or twice daily administration. Tesamorelin is more often discussed in once-daily protocols at 1–2 mg, and its longer effective duration means less frequent adjustment is typically needed in protocol designs. Both are compared against direct GH-secretagogue peptides in research discussions about pulse timing.

Evidence Comparison

Tesamorelin has a stronger and more recent published evidence base, anchored by the clinical trials supporting its FDA approval in lipodystrophy and by ongoing body composition research. Sermorelin has been used clinically for longer but has a thinner published trial record in current literature. For evidence maturity, Tesamorelin is generally the more documented comparison reference.

Frequently asked questions

Which is better, Sermorelin or Tesamorelin?

Sermorelin and Tesamorelin are researched for different contexts, so the better choice depends on study goals, mechanism priorities, and protocol design.

Can you stack Sermorelin and Tesamorelin?

Some researchers evaluate Sermorelin and Tesamorelin together, but combination design depends on evidence quality, safety considerations, and whether overlapping mechanisms are appropriate for the research question.